n/a
Article Publish Status: FREE
Abstract Title:

Erucin exhibits vasorelaxing effects and antihypertensive activity by HS-releasing properties.

Abstract Source:

Br J Pharmacol. 2020 Feb ;177(4):824-835. Epub 2019 Apr 15. PMID: 30825379

Abstract Author(s):

Alma Martelli, Eugenia Piragine, Valentina Citi, Lara Testai, Eleonora Pagnotta, Luisa Ugolini, Luca Lazzeri, Lorenzo Di Cesare Mannelli, Onorina Laura Manzo, Mariarosaria Bucci, Carla Ghelardini, Maria Cristina Breschi, Vincenzo Calderone

Article Affiliation:

Alma Martelli

Abstract:

BACKGROUND AND PURPOSE: Hydrogen sulfide (HS)-releasing agents are viewed as potential antihypertensive drugs. Recently, natural isothiocyanates emerged as original HS-donor agents. Among them, erucin, present in some edible cruciferous plants, shows suitable HS-releasing properties and features of "druggability." The aim of this work was to investigate the erucin-mediated release of HS inside vascular cells, its vasorelaxing effects, and activity on BP of normo and hypertensive animals.

EXPERIMENTAL APPROACH: Intracellular HS-release and the hyperpolarizing effect of erucin were tested using fluorescent dye, in human aortic smooth muscle cells (HASMCs). Its direct vasorelaxing effect and ability to inhibit noradrenaline-induced vasoconstriction were evaluated on endothelium-intact or -denuded rat aortic rings. Its vasodilator properties were tested in coronary arteries using Langendorff-perfused rat hearts. Finally, erucin's antihypertensive activity was evaluated in vivo in normotensive and spontaneously hypertensive rats (SHRs) by recording systolic BP using the tail-cuff method.

KEY RESULTS: Erucin induced the release of HS inside HASMCs. Moreover, erucin hyperpolarized the membrane of HASMCs membrane in a concentration-dependent manner. It induced vasodilatation of rat aortic rings, in endothelium-denuded vessels. This effect was further improved by the presence of endothelial NO. When pre-incubated with rat aortic rings, erucin induced concentration-dependent inhibition of noradrenaline-induced vasoconstriction. Erucin did not affect basal coronary flow but restored the flow to normal in pre-contracted coronary vessels. Finally, in vivo, erucin decreased systolic BP in SHRs by about 25%, and restored the BP to values observed in normotensive rats.

CONCLUSIONS AND IMPLICATIONS: Erucin is an HS donor endowed with vasorelaxing and antihypertensive effects.

LINKED ARTICLES: This article is part of a themed section on Hydrogen Sulfide in Biology&Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc.

Study Type : Animal Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.